Roche reports FY24 group sales CHF 60.5B vs. CHF 58.7B last year

Reported Core EPS CHF 18.80 vs. CHF $18.57 last year. Group sales grew by 7% at constant exchange rates, driven by strong demand for both medicines and diagnostics. Excluding COVID-19, Group sales increased by 9%. COVID-19 will not adversely impact results from 2025 onwards. The fourth quarter was the third consecutive quarter of 9% sales growth, highlighting the very positive momentum. Roche (RHHBY) CEO Thomas Schinecker: “2024 was a strong year for Roche. In the fourth quarter, we continued our very positive momentum for the third consecutive quarter with Group sales growth of 9%. Core earnings per share exceeded the guidance raised at half year. We are proud to have made a positive impact on patients’ lives in 2024 with the launch of two new medicines – Itovebi for a hard-to-treat breast cancer and PiaSky for a serious blood disorder – as well as our new solution for continuous blood glucose monitoring and our innovative system for fully automated mass spectrometry. Last year, we substantially strengthened our pipeline through the acceleration of internal key programmes and new partnerships and acquisitions such as Poseida Therapeutics for cell therapy in oncology and autoimmune diseases. Roche is well positioned for future growth.”